References
1. Avdeeva Zh.I., Soldatov A.A., Kiselevsky M.V., Medunitsyn N.V. Antitumor monoclonal antibodies. Immunologiya [Immunology]. 2017; 38 (5): 256–70. (in Russian)
2. Vatutin N.T., Sklyannaya E.V., El-Khatib M.A., Taradin G.G. Cardiovascular complications of anticancer therapy: definition, etiology, epidemiology, pathogenesis, classification (part I). Rossiyskiy onkologicheskiy zhurnal [Russian Journal of Cancer]. 2017; 22 (6): 345–50. (in Russian)
3. Yang X., Li X., Yuan M., Tian C., Yang Y., Wang X., et al. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018; 9: 1058.
4. Nuriev R.I., Karaulov A.V, Kisielewsky M.V. Novel treatment strategies for patients with cancer: immunotherapeutic approach. Immunologiya [Immunology]. 2017; 38 (1): 39–48. (in Russian)
5. Ovchinnikov A.G., Skorobogatova A.V., Semiglazova T.Yu., Kozyavin N.A., Ageev F.T., Chazova I.E. Cardiotoxicity of trastuzumab: mechanisms of development, diagnosis, treatment. Voprosy oncologii [Problems in Oncology]. 2016; (6): 719–31. (in Russian)
6. Kobalava Zh.D., Shavarova E.K. Hypertension related to the antitumor treatment with angiogenesis inhibitors: an iatrogenic hypertension. Arterial’naya gipertenziya [Arterial Hypertension]. 2018; 24 (4): 384–95. (in Russian)
7. Hiller L., Dunn J. A., Loi S., et al. Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer. 2018; 18 (1): 391.
8. Loibl S., Gianni L. HER2-positive breast cancer. Lancet. 2017; 389 (10 087): 2415–29.
9. Vasyuk Yu.A., Yushchuk E.N., Nesvetov V.V. Cardiooncology: a new challenge of our time. Cardiovascular complications of antitumor treatment. Moscow : Klinmed Konsulting, 2019: 100 p. (in Russian)
10. Chazova I.E., Oshchepkova E.V., Kirillova M.Yu., Stenina M.B. Risk of hypertension development in patients with oncological diseases under anticancer treatment. Consilium Medicum. 2016; 18 (1): 16–20. (in Russian)
11. Vasyuk Yu.A., Shupenina E.Yu., Novosel E.O., Agapov I.S. Heart rhythm and conduction disorders as manifestations of cardiotoxicity of anticancer treatment: myth or reality? Sibirskiy meditsinskiy zhurnal [Siberian Medical Journal]. 2020; 35 (1): 13–21. (in Russian)
12. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67 (1): 7–30.
13. Chazova I.E., Tyulyandin S.A., Vitsenya M.V., et al. Clinical Manual for Diagnosis, prevention and treatment of cardiovascular complications of cancer therapy. Part I. Sistemnye gipertenzii [Systemic Hypertension]. 2017; 14 (3): 6–20. (in Russian)
14. Manrique C.R., Park M., Tiwari N., Plana J.C., Garcia M.J. Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin Med Insights Cardiol. 2017; 11: 1–12.
15. Seliverstova D.V., Evsina O.V. Cardiotoxicity of chemotherapy. Serdtse [Heart]. 2016; 15 (1). 50–7. (in Russian)
16. Nicolazzi M.A., Carnicelli A., Fuorlo M., et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018; 22 (7): 2175–85.
17. Martinello R., Becco P., Vici P., Airoldi M., Del Mastro L., Garrone O., et al. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. Breast J. 2019; 25 (3): 444–9.
18. Truschin A.Yu. Trastuzumab-induced cardiotoxicity - interdisciplinary problem of modern medicine. Mezhdunarodniy nauchno-issledovatel’skiy zhurnal [International Research Journal]. 2019: 4 (82): 118–23. (in Russian)
19. Yuan M., Tse G., Zhang Z., Han X., Wu W.K.K., Li G., et al. The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and meta-analysis. Cardiovasc Ther. 2018; 36 (6): e12475.
20. Modesto Dos Santos V., Modesto Dos Santos L.A. Cardiotoxicity in chemotherapeutic agents. Russ Open Med J. 2021; 10: e0106.
21. Lancellotti P., Galderisi M., Donal E., et al. Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Fail. 2017; 4: 312–8.
22. Touyz R.M., Lang N.N., Herrmann J., van den Meiracker A.H., Danser A.H.J. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017l; 70 (2): 220–6.
23. Ky B. Priorities in the cardiovascular care of breast cancer survivors. J Oncol Pract. 2018; 14 (4): 205–11.
24. Riccio G., Coppola C., Piscopo G., et al. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? Hum Vaccin Immunother . 2016; 12: 1124–31.
25. Osman M., Elkady M. A prospective study to evaluate the effect of paclitaxel on cardiac ejection fraction. Breast Care. 2017; 12 (4): 255–9.